Alarm.com acquires majority stakes in U.S.-based software firm OpenEye
Category: #business  By Pankaj Singh  Date: 2019-10-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Alarm.com acquires majority stakes in U.S.-based software firm OpenEye

The cloud-based video services market (also known as Video-Surveillance-as-a-Service (VSaaS)) is expanding at a significant pace as legacy solutions shift to cloud-centric architectures. According to IHS Markit report, the Video Surveillance Market is forecasted to rise from 9% of total spending in 2018 to 15% by 2022. To tap this growing market, companies are strengthening their offering through acquisition of industry leaders in this space.

Alarm.com is one such U.S.-based technology company that has reportedly announced the acquisition of majority-stake in OpenEye, one of the leading solution provider company in cloud-based video surveillance commercial market.

Reportedly, OpenEye offers are optimized for commercial consumers that require extensive video recording capabilities along with remote viewing, administration and diagnostic reporting. After this acquisition, service providers who are partnered with Alarm.com would get a cutting-edge solution to comprise commercial accounts of any size.

Sources cite that the combination of Alarm.com and OpenEye would provide a comprehensive array of cloud-based services including video, access control, intrusion, and automation for international as well as domestic enterprises of all sizes. After the acquisition, OpenEye will become a subsidiary of Alarm.com. However, it will continue to operate under the OpenEye brand and will lead by the current management team.

Reportedly, OpenEye Web Services will continue to work as an open cloud platform and will stay committed to expanding its integrated devices and ecosystem of technology partners. Meanwhile, Alarm.com plans to invest more in OpenEye’s growth and expand its headquarters existence Liberty Lake, Washington.

Steve Trundle, President, and CEO of Alarm.com, states that OpenEye had consistently shown that they are a market leader in video-surveillance-as-a-service space and their company is excited to help it continuously grow its business.

He added that OpenEye has a robust partner and consumer list and the company’s priority is to ensure all partners would continue to experience best-in-class service. Additionally, with the help of OpenEye, the offerings available to Alarm.com partners will enhance in the commercial space, said Trundle.

Source Credit -https://www.businesswire.com/news/home/20191021005846/en/Alarm.com-Acquires-OpenEye-Expand-Commercial-Solutions

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Merck acquires Calporta Therapeutics from COI Pharmaceuticals
Merck acquires Calporta Therapeutics from COI Pharmaceuticals
By Pankaj Singh

Merck will pay up to $576 million for the acquisition   Preclinical TRPML1 has the potential to treat neurodegenerative and lysosomal disorders COI Pharmaceuticals has recently announced that Merck, also called MSD outside Canada and the U...

Personalis unveils new service for cancer whole genome sequencing
Personalis unveils new service for cancer whole genome sequencing
By Pankaj Singh

  The new launch of the services will help the company expand its oncology portfolio Personalis has been able to sequence more than 40,000 MVP samples since 2013. Personalis, Inc., a leading advanced genomics firm for cancer, recently unve...

Celltrion depicts CT-P13 SC efficacy for treating rheumatoid arthritis
Celltrion depicts CT-P13 SC efficacy for treating rheumatoid arthritis
By Pankaj Singh

Celltrion Healthcare, a biopharmaceutical company, recently announced data from a study further investigating efficacy, safety, immunogenicity & pharmacokinetics of CT-P13 SC, over a period of 1-year treatment. The study focuses on the results ac...